trial

52-week Open Label Safety-Tolerability Study

NCTId NCT07369154
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 900 (estimated)
Sponsored by LB Pharmaceuticals Inc.
Primary completion 2028-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
900 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-04
Primary completion
2028-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LB-102

Sponsors

LB Pharmaceuticals Inc.Lead Sponsor

Sites

23 total
Chandler, United StatesBentonville, United StatesLittle Rock, United StatesLittle Rock, United StatesAnaheim, United StatesCerritos, United StatesCulver City, United StatesCulver City, United StatesSan Diego, United StatesHollywood, United StatesMiami Lakes, United StatesWest Palm Beach, United States

Linked catalysts

1
52-week Open Label Safety-Tolerability Study — primary completion2028-12

Facts & assertions

4 sourced
Enrollment
900
Phase
PHASE3
Primary Completion Date
2028-12
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
LB-102
drug
lead_sponsor
LB Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication